Market Closed -
Other stock markets
|
Pre-market 02:53:46 am | |||
206 EUR | -1.10% | 206.8 | +0.39% |
Apr. 23 | SARTORIUS STEDIM BIOTECH : Barclays reaffirms its Neutral rating | ZD |
Apr. 22 | Sartorius Stedim: in the red with brokerage comments | CF |
Sales 2024 * | 2.94B 3.16B | Sales 2025 * | 3.35B 3.6B | Capitalization | 20.05B 21.56B |
---|---|---|---|---|---|
Net income 2024 * | 343M 369M | Net income 2025 * | 459M 494M | EV / Sales 2024 * | 7.59 x |
Net Debt 2024 * | 2.27B 2.44B | Net Debt 2025 * | 2.15B 2.32B | EV / Sales 2025 * | 6.63 x |
P/E ratio 2024 * |
57.1
x | P/E ratio 2025 * |
41.2
x | Employees | 10,493 |
Yield 2024 * |
0.36% | Yield 2025 * |
0.53% | Free-Float | 31.97% |
Latest transcript on Sartorius Stedim Biotech
1 day | -1.10% | ||
1 week | -1.76% | ||
Current month | +1.48% | ||
1 month | -18.22% | ||
3 months | -17.93% | ||
6 months | +10.31% | ||
Current year | -13.99% |
Managers | Title | Age | Since |
---|---|---|---|
René Fáber
CEO | Chief Executive Officer | 48 | 19-03-25 |
Chairman | 59 | 07-06-28 | |
Chief Tech/Sci/R&D Officer | 59 | 09-04-28 |
Members of the board | Title | Age | Since |
---|---|---|---|
Henri Riey
BRD | Director/Board Member | 62 | 07-06-28 |
Chairman | 59 | 07-06-28 | |
Susan Dexter
BRD | Director/Board Member | 67 | 15-04-06 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.42% | 18 M€ | +5.44% | - | |
0.35% | 5 M€ | +4.56% |
Date | Price | Change | Volume |
---|---|---|---|
24-05-06 | 206 | -1.10% | 31,935 |
24-05-03 | 208.3 | +1.17% | 59,677 |
24-05-02 | 205.9 | +1.43% | 108,028 |
24-04-30 | 203 | -3.20% | 51,248 |
Real-time Euronext Paris, May 06, 2024 at 11:35 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-13.99% | 21.6B | |
-4.02% | 184B | |
-0.75% | 109B | |
-2.97% | 68.37B | |
+4.48% | 51.56B | |
+9.09% | 44.69B | |
+4.37% | 41.49B | |
+3.12% | 26.75B | |
+4.10% | 26.7B | |
+15.38% | 25.68B |
- Stock Market
- Equities
- DIM Stock